Hsbc Holdings PLC Has $96.56 Million Stock Holdings in Kenvue Inc. $KVUE

Hsbc Holdings PLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 10.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,618,177 shares of the company’s stock after buying an additional 511,809 shares during the quarter. Hsbc Holdings PLC’s holdings in Kenvue were worth $96,555,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Norges Bank acquired a new position in shares of Kenvue in the fourth quarter worth $756,862,000. Independent Franchise Partners LLP boosted its position in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after purchasing an additional 17,343,785 shares during the last quarter. Sculptor Capital LP grew its stake in Kenvue by 1,023.5% in the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after purchasing an additional 11,739,328 shares in the last quarter. Capitolis Liquid Global Markets LLC grew its stake in Kenvue by 1,116.8% in the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock valued at $188,905,000 after purchasing an additional 10,050,999 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new position in Kenvue in the fourth quarter valued at about $162,193,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.59% of the company’s stock.

Kenvue Stock Down 0.2%

Shares of KVUE opened at $18.94 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company has a 50-day simple moving average of $18.20 and a 200-day simple moving average of $17.86. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The firm has a market capitalization of $36.37 billion, a P/E ratio of 22.28, a P/E/G ratio of 1.44 and a beta of 0.47.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same period last year, the business earned $0.24 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KVUE shares. Citigroup cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays cut their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Finally, UBS Group raised their price objective on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $19.50.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.